North America Autoimmune Diagnostics Market

North America Autoimmune Diagnostics Market Size (2023 to 2028)

The size of the Autoimmune Diagnostics Market size in North America was worth USD 6.08 billion in 2023. It is estimated to reach USD 7.19 billion by the end of 2028, with a growing potential of 3.40%.

NIH expected that up to 23.5 million Americans have an Autoimmune disorder. In comparison, heart diseases up to 22 million and cancer affects up to 9 million people in America. So, NIH estimates that the annual direct health spending on autoimmune diagnostics is nearly 100 billion (USD). With 50 million Americans living and coping with autoimmune disorders, more than 75% of them are women. Autoimmune diseases affect women three times more than men. Some of these diseases have an even higher incidence in women. Autoimmune diseases have been mentioned in the top ten leading causes of the deaths among U.S. women aged 65 and younger. So, these diseases represent the fourth-largest cause of disability among women in the United States.

The North American Autoimmune Disease Diagnostics market is primarily driven by a few key factors such as the increasing prevalence of autoimmune diseases, patient awareness of growing health issues, increasing healthcare spending, increasing initiatives government, and the rise of automation technologies leading to greater sensitivity, faster and more comfortable performance of disease prevention and diagnostic test results. North America occupies a leading position in the autoimmune disease diagnostics market due to the increasing incidence of autoimmune diseases such as rheumatoid arthritis, type I diabetes, increasing infrastructure health care, and increasing per capita income, and strengthening multinationals in their distribution network followed by Europe. The major driving factors that have driven the growth of the Autoimmune Disease Diagnostics market in this region are the ever-increasing regulatory scenario being watched by various organizations such as World Health Organization (WHO) for safety issues and health, technological progress in the search for new techniques, increased funding in public and private sectors

Supportive government policies, and increasing public awareness, increasing the occurrence of Autoimmune disorders, advancements in health care, and improved laboratory techniques are the factors driving the growth of the market.

However, the autoimmune disease diagnostics market is faced with several challenges, such as a high frequency of false-positive results and long turnaround time for diagnostic test results. Diagnosis of autoimmune diseases Market testing is expensive, which is a significant limitation for the market. The autoimmune disease diagnostics market faces enormous challenges due to inadequate knowledge of various conditions and diagnostic measures. Low-income companies and growing economies are presenting themselves to solve these problems for the autoimmune disease diagnostics market. The lack of healthcare professionals with the skills to manage and treat autoimmune diseases will hamper the industry's growth for years to come.

This report on the North America Autoimmune Diagnostics Market has been segmented & sub-segmented into the following categories:

• By Test Type: Autoantibody Tests, Antinuclear Antibody Tests, Complete Blood Count (CBC), C-reactive protein (CRP), Comprehensive Metabolic Panel, Urinalysis, Erythrocyte Sedimentation Rate (ESR), and Others
• By Disease Type: Localized Autoimmune Disease Diagnostics (Graves' Disease, Hashimoto's Thyroiditis, Multiple Sclerosis, Type 1 Diabetes, Psoriasis, And Others), Systemic Autoimmune Disease Diagnostics (Rheumatoid Arthritis (RA), Ankylosing Spondylitis and Systemic Lupus Erythematosus (SLE))
• By End User: Hospitals, Research Centers and Diagnostic Laboratories
• By Country: the United States, Canada, and Rest of North America

Geographically, In North America, the U.S. and Canada have emerged as the most lucrative markets for autoimmune disease diagnostics. So, both these countries boast sophisticated healthcare infrastructure with advanced laboratory techniques and increasing awareness about various medical procedures. The overall high healthcare expenditure across the region puts North America at the front in the global autoimmune disease diagnostics market

The North American autoimmune disease diagnostics market has been dominated by the US autoimmune disease diagnostics market and is expected to show a positive trend throughout the projection period. The Canadian autoimmune disease diagnostics industry is expected to keep pace with the US autoimmune disease diagnostics market progress at a CAGR of 2.0% during the forecast period. The increasing prevalence of autoimmune diseases in Canada is driving market growth. According to the recently published article, approximately 5.2 million Canadians are affected by autoimmune diseases. Canada devoted about 11.7% of its total GDP to the health sector in 2020. Health care spending in Canada is continually increasing, and the trend is expected to continue for the forecast period. Besides, the growing research and development activities in the country will significantly impact the growth of the autoimmune diagnostics industry in Canada.

Some of the major companies dominating the North America Autoimmune disease market by their products and services include Bio-Rad, Siemens Healthcare, Abbott Laboratories, Crescendo Bioscience, Roche Diagnostics SQI Diagnostics, AESKU Diagnostics, INOVA Diagnostics Inc., BioMerieux SA, Beckman Coulter Inc., Hemagen Diagnostics, Quest Diagnostics, Eli Lilly, GlaxoSmithKline Plc.